All News
Rheum Manpower Needs - More Programs! (12.2.2022)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Rheum Drugs & IDSA Guidelines to Treat COVID-19
The Infectious Diseases Society of America has recently updated its recommendations with regards to the treatment of severely ill, hospitalized COVID-19 infected patients and also about the appropriate use of anti-IL-6, JAKs and colchicine.
Read Article
RECITAL Trial: RTX vs. CTX in CTD-ILD
A UK study suggests the equivalent outcomes when patients with interstitial lung disease (ILD) associated with connective tissue disease (CTD) are treated with either intravenous rituximab (RTX) or cyclophosphamide (CTX), but with fewer adverse events with RTX.
Read Article
Impressive free read and review of Neutrophils and Netosis in Autoimmune and Autoinflammatory disorders (Nature Reviews) from Kapland & Wigerblad at the NIH. https://t.co/w4cIwcQMkt https://t.co/ReA9xM2X4j
Dr. John Cush RheumNow ( View Tweet)
Topic Podcasts - Lupus Part2
#ACR22 Daily Recap: Saturday Recap New Treatments for SLE?
https://t.co/uRI3Q3eI6E https://t.co/wBXfXw7z8J
Links:
Dr. John Cush RheumNow ( View Tweet)
Just Can’t Get Enough of Hydroxychloroquine
Several studies on HCQ dosing were presented in the poster and abstract sessions. HCQ has numerous benefits backed by evidence and unless absolutely contraindicated, patients should be maintained on it. Yet...
https://t.co/n8drUDDDjh https://t.co/AIoV3s2VhJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Steroid injections worsen knee arthritis
Two studies comparing injections commonly used to relieve the pain of knee osteoarthritis found that corticosteroid injections were associated with the progression of the disease.
https://t.co/v7cDBKfM9c https://t.co/sbJ1ro0orW
Links:
Dr. John Cush RheumNow ( View Tweet)
Low Dose IL-2 Therapy in Sjögren’s
There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that lLD-IL-2 was effective and well tolerated in patients with pSS, with evidence of restored immune balance.
https://t.co/0obaV0wnGX https://t.co/vgy91cYYvp
Links:
Dr. John Cush RheumNow ( View Tweet)
Topic Podcasts - Lupus Part1
-A Novel Treatment Response Measurement Tool for Lupus
-Breakthrough COVID infection in SLE during Omicron era
Effect of voclosporin in class V lupus nephritis
and more.
https://t.co/RVhpZtoo6b https://t.co/jjOZbLZN9m
Links:
Dr. John Cush RheumNow ( View Tweet)
Pre-RA Pharmacological Interventions: Delaying is not Enough
Dr. Aurelie Najm reports on both the Great Debate as well as abstracts 0530, 1603 at #ACR22
https://t.co/n8hzJMpmWO https://t.co/8OISSK34No
Links:
Dr. John Cush RheumNow ( View Tweet)
The complexity of opioid use in spondyloarthritis
A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized.
https://t.co/B4Q7Af7doF https://t.co/sdjHoa8shP
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR22: Polymyalgia Rheumatica in the Spotlight
One of the enduring legacies of #ACR22 for Dr. Putman ( @EBRheum) will be the emphasis on PMR. Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run.
https://t.co/SYKT3a03Tc https://t.co/9CIRp66vSK
Links:
Dr. John Cush RheumNow ( View Tweet)
Estimated Global SLE market size was $1.46 billion in 2020, with a global (7 Major countries) prevalence of 651,965 in 2020; and a USA prevalence of 351,176 SLE cases. https://t.co/f4Tghup5PC https://t.co/p1w9KFQR4z
Links:
Dr. John Cush RheumNow ( View Tweet)
1602 pemphigus pts Rx w/ rituximab vs azathioprine or MMF. RTX pts had lower risk of MI (RR 0.45; P = .01), CVA (RR, 0.42; P < .001), PVD (0.47), HTN (0.48), hyperlipidemia (0.45), NIDDM (0.63), obesity (0.49). Mortality equal betw groups https://t.co/uvDDU5z8gp https://t.co/kJAg5xRKHz
Links:
Dr. John Cush RheumNow ( View Tweet)
Etoricoxib and Celecoxib may lower CVA risk. Taiwanese study of 10,857 newly Dx RA pts. Coxib use vs non-use compared re: future CVA. Celecoxib pts had reduced CVA (HR 0.67 @200/d; HR 0.22 if <3.5 yrs). Etoricoxib also (HR 0.35; 0.16–0.80) https://t.co/GQEp8N0uZb https://t.co/TxfyIemzBT
Links:
Dr. John Cush RheumNow ( View Tweet)
NRMP Results for rheumatology 2022 :
- Adult Rheum: 97.8% of 272 fellow positions filled (41% US grads) (371 applied)
- Pediatric Rheum: 69.2% of 39 positions filled (54% US grads) (29 applied)
WE NEED MORE ADULT PROGRAMS AND MORE INTEREST IN PEDI RHEUM https://t.co/YpMhTPnDM4 https://t.co/Aa3EV57yij
Links:
Dr. John Cush RheumNow ( View Tweet)
AURORA1 RCT
📍Efficacy of voclosporin in LN III-V with UPC > 1.5g
💊VOC 23.7 mg BID vs. PCB
💊All got MMF 1g BID and GC
🥇#1 outcome: UPC < 0.5, stable 🫘 fx, ❌ GC > 10 mg
-40% VOC v. 23% PCB (sig)
-all measures favored VOC, but only sig. for UPC < 0.5
Catherine Sims, MD DrCassySims ( View Tweet)
Topic Podcasts - JAK TYK2
https://t.co/DqfEj955aw https://t.co/HRj28berzF
Links:
Dr. John Cush RheumNow ( View Tweet)
A great read from Dr. Anthony Fauci as he steps down from leading the NIH NIAID research for nearly 40 years. He writes on pundits, need for specialty growth, evolution of vaccines and "it aint over till its over" is now "its never over" https://t.co/z0noGckIvx https://t.co/DJKG88V1mc
Links:
Dr. John Cush RheumNow ( View Tweet)
Estimated worldwide market for DMARDs in 2022 was $20.7 billion USD and is expected to rise at a 3.5% annual growth rate to $ 272 billion USD by 2030 https://t.co/futp7249rF https://t.co/QgxJR7TQNw
Links:
Dr. John Cush RheumNow ( View Tweet)